Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2301912 | 1.00 | MEN1 (0.34) | MEN1KMT2AHCAR2MGLLL3MBTL1 | |
| SCHEMBL10242853 | 0.84 | MEN1 (0.43) | MEN1KMT2AHCAR2MGLL | |
| SCHEMBL3348695 | 0.84 | MEN1 (0.40) | MEN1KMT2AMGLLCREBBPPTPN1 | |
| SCHEMBL3348688 | 0.84 | MEN1 (0.40) | MEN1KMT2AMGLLCREBBPPTPN1 | |
| SCHEMBL5926286 | 0.80 | MAPT (0.38) | MEN1KMT2AHCAR2MGLLL3MBTL1 | |
| SCHEMBL5926284 | 0.80 | MAPT (0.38) | MEN1KMT2AHCAR2MGLLL3MBTL1 | |
| SCHEMBL18290965 | 0.78 | MAPT (0.42) | MEN1KMT2AHCAR2MGLLL3MBTL1 | |
| SCHEMBL6903532 | 0.77 | MAPT (0.48) | MEN1KMT2AHCAR2MGLLALDH1A1 | |
| SCHEMBL3074618 | 0.75 | MEN1 (0.39) | MEN1KMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL6922396 | 0.75 | MAPT (0.46) | MEN1KMT2AHCAR2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513234-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513234-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2349276-A2 | HIV INTEGRASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100087419-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-08 | — | — | US | disclosed |
| US-20100087419-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087419-A1 | HIV INTEGRASE INHIBITORS | POLB, CCNB1, POLR2A | MEN1 3763/4885KMT2A 1215/4885HCAR2 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.